Integrated Biopharma Inc gross margin has been in long-term decline. The average rate of decline per year is -5%.
The historical rank and industry rank for Integrated Biopharma's Gross Margin % or its related term are showing as below:
INBP'
s Gross Margin % Range Over the Past 10 Years
Min: 6.62 Med: 12.6 Max: 14.92
Current: 6.62
During the past 13 years, the highestGross Margin % of Integrated Biopharma was 14.92%. The lowest was 6.62%. And the median was 12.60%.
INBP's Gross Margin % is ranked worse than 89.22% of 1809
companies
in the Consumer Packaged Goods industry
Industry Median: 25.08
vs INBP: 6.62
Integrated Biopharma had a gross margin of 4.52% for the quarter that ended in Dec. 2023 => No sustainable competitive advantage
The 5-Year average Growth Rate of Gross Margin for Integrated Biopharma was -5.00% per year.
Integrated Biopharma Gross Margin % Historical Data
The historical data trend for Integrated Biopharma's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Integrated Biopharma's Gross Margin %
For the Packaged Foods subindustry, Integrated Biopharma's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Integrated Biopharma's Gross Margin % Distribution in the Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, Integrated Biopharma's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Integrated Biopharma's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Integrated Biopharma had a gross margin of 4.52% for the quarter that ended in Dec. 2023 => No sustainable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Integrated Biopharma Gross Margin % Related Terms
Thank you for viewing the detailed overview of Integrated Biopharma's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.
Integrated Biopharma (Integrated Biopharma) Business Description
Integrated Biopharma Inc is a pharmaceutical company engaged in manufacturing, distributing, marketing, and selling vitamins, nutritional supplements, and herbal products. It operates in two segments; Contract Manufacturing and Other Nutraceutical Businesses. It serves the needs of the nutraceutical industry by directly doing business as Chem International Inc. and through its operating subsidiaries; Manhattan Drug Company, Inc., AgroLabs, Inc., IHT Health Products, Inc. and MDC Warehousing and Distribution, Inc. The company generates maximum revenue from the Contract Manufacturing segment. The business operates and generates the majority of revenue from the United States.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
INBP has been successfully added to your 